By Meaghan Lee Callaghan
The seven newly appointed members of the Advisory Committee on Immunization Practices voted 5-to-2 to recommend clesrovimab-cfor (Enflonsia, Merck), the second long-acting monoclonal antibody administered to infants to prevent respiratory syncytial virus infection.
Clesrovimab is recommended for infants 8 months of age and younger who are born during or entering their first RSV season. The FDA approved the monoclonal antibody (Mab) earlier this month.
At the first